Telehealth Allied Health Care With People Who Have Parkinson's Disease Living in Rural Nevada and Wyoming

Sponsor
University of Wyoming (Other)
Overall Status
Unknown status
CT.gov ID
NCT03381898
Collaborator
University of Nevada, Las Vegas (Other)
20
2
1
18.9
10
0.5

Study Details

Study Description

Brief Summary

The investigators have developed a three-part allied health care intervention to be delivered via telehealth. These interventions are usually provided face-to-face. Telehealth access to healthcare is needed for people with Parkinson's disease living in rural locations, where providers are sparse and long travel times are often not feasible because of weather conditions, as well as the hallmark symptom of Parkinson's disease, movement disorders

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Telehealth Exercise, speech therapy, medication management
N/A

Detailed Description

Parkinson's Disease & Allied Health. Parkinson's disease (PD), the second most common neurodegenerative disorder affecting more than a million people in the U.S., has no known cause or cure. Persons with PD use prescription medications and behavioral interventions to alleviate key problems such as walking, handling objects, and speaking. Individuals with PD, accessing multidisciplinary allied health care intervention, have shown functional gains. Without these ongoing, coordinated services, persons with PD become even more debilitated, and this can hasten a decline in their quality of life.

Parkinson's Disease & Rurality. For those in rural areas, there is a critical health disparity. People who live rurally contend with isolation. Wyoming and Nevada's population density are ranked 49th and 42nd. In conjunction with this low population density and mountainous terrain, individuals experience tremendous burdens including traveling long distances to see health care providers with expertise in treating PD. These factors contribute to the struggle of rural Americans with PD to manage this complicated, chronic disease.

Parkinson's Disease & Telehealth. Telehealth technology has successfully allowed the delivery of neurology care via "virtual house calls" with rural residents with PD. The virtual house call model was determined to be feasible and promising for specialist care in underserved rural areas. However, telehealth delivery of allied health care should also be examined.

Thus, the investigators propose an exploratory Phase 2 Behavioral Clinical Trial to determine feasibility, safety, and signal of efficacy for telehealth coordinated allied health care for persons with Parkinson's disease in rural Wyoming and Nevada. All 20 participants will be in one arm receiving telehealth exercise, speech therapy, and medication management for eight weeks.

Specific Aims:
For persons with Parkinson's disease in rural Wyoming and Nevada, the investigators will:

Aim 1 Test the feasibility of speech therapy, exercise therapy and medication management coordinated through telehealth.

Aim 2 Determine the safety of the coordinated telehealth speech therapy, exercise therapy, and medication management.

Aim 3 Measure signal of efficacy for telehealth outcomes

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
This is a feasibility and safety trial of a single arm a telehealth intervention (pharmacy, physical therapy, and speech therapy) to people with Parkinson's disease.This is a feasibility and safety trial of a single arm a telehealth intervention (pharmacy, physical therapy, and speech therapy) to people with Parkinson's disease.
Masking:
None (Open Label)
Masking Description:
The outcomes assessment and the care providers will be blind to the aims of the study.
Primary Purpose:
Treatment
Official Title:
Decreasing Health Disparities for Parkinson's Disease in Rural Communities: Assessing Feasibility of Coordinated Telehealth to Deliver Allied Health Care of Medication Management, Physical Therapy, and Speech Therapy
Actual Study Start Date :
Nov 2, 2017
Anticipated Primary Completion Date :
Dec 31, 2018
Anticipated Study Completion Date :
May 31, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Telehealth Coordinated Allied Health

rural persons with Parkinson's disease will receive telehealth exercise, speech therapy, medication management for 8 weeks. Exercise, speech therapy, and medication management are usual care for persons with Parkinson's disease. Having the 3 areas coordinated in delivery via telehealth is the new delivery that our aims address

Behavioral: Telehealth Exercise, speech therapy, medication management
Telehealth exercise once per week, speech therapy 4 times per week, medication management once per week

Outcome Measures

Primary Outcome Measures

  1. Aim 1: Feasibility of the 8-week telehealth program [8 weeks]

    The number of sessions completed and ability to use the necessary technology.

  2. Aim 2: Safety of the 8-week telehealth program [8 weeks]

    The frequency and nature of adverse events during participation of the telehealth program.

  3. Aim 3: Change in Signal of efficacy of the telehealth program - overall [0, 8, 24 weeks]

    The change in quality of life between baseline at the beginning of the study and after the 8 week intervention. In addition, change will also be measured between the end of the 8 week intervention and 18 weeks later (24 weeks from the baseline). This quality of life measures is a self-report, PD-specific Parkinson's Disease Questionnaire 39 (PDQ39). There are 39 items in 8 subsections (mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, bodily discomfort). Each item ranges from 0 (never) to 4 (always). The overall score and subsection scores are calculated by taking the means of each item divided by the total for that section; thus, converting the score into a percentage with higher percentages equating to more disability.

Secondary Outcome Measures

  1. Aim 3: Signal of efficacy of the telehealth program - pharmacy [8, 24 weeks]

    Change in pill count (i.e., how many pills of each prescription are taken) over the period of the study.

  2. Aim 3: Signal of efficacy of the telehealth program - physical therapy 1 [0, 8, 24 weeks]

    Change in 30 second Sit-to-Stand test which measures how many times the participant can stand in 30 seconds.

  3. Aim 3: Signal of efficacy of the telehealth program - physical therapy 2 [0, 8, 24 weeks]

    Change in Parkinson's Fatigue Scale, which is a self-report measure of fatigue. This scale measures 16 items using a Likert scale with a low score of 16 (low fatigue) and a high score of 80 (high fatigue).

  4. Aim 3: Signal of efficacy of the telehealth program - physical therapy 3 [0, 8, 24 weeks]

    Change in Unified Parkinson's Disease Rating Scale II (UPDRS II), which is a self-report of PD-specific motor aspects of experiences of daily living. There are 13 items with scores ranging from 0 (normal) to 4 (severe). Thus, a score of 0 indicates normal function whereas a score of 52 (the highest possible score) suggestive of severe motor deficits with activities of daily living.

  5. Aim 3: Signal of efficacy of the telehealth program - speech therapy 1 [0, 8, 24 weeks]

    Change in self-report Communication Effectiveness Scale, which is an 8 question scale using a 4-point likert scale on how the participant social participation is affected by his speech and communication. The scores range from 0 (not effective) to 32 (very effective communication in all situations).

  6. Aim 3: Signal of efficacy of the telehealth program - speech therapy 2 [0, 8, 24 weeks]

    Change in Vocal sound level intensity using the Lee Silverman Voice Treatment (LSVT) Companion Software which measures speech intensity. Changes in vocal sound level could range from - 6 decibel (dB) (reduced loudness) to at least + 6dB which is the average change and is perceptually noticeable.

Eligibility Criteria

Criteria

Ages Eligible for Study:
30 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Speak English

  • Are 30 years or older

  • Have been diagnosed with Parkinson's Disease by a primary care provider

  • Allow for us to communicate about you to your primary care provider (i.e., physician, nurse practitioner, or physician assistant)

  • Can stand alone for 10 min without holding on to anything

  • Are taking at least one medication for Parkinson's Disease

  • Are willing the participate in an 8-week study

  • Will provide your physical address, your phone number, and an emergency contact's phone number for us to use if an emergency occurs during your telehealth session.

Exclusion Criteria:
  • Have dementia or problems following directions

  • Have a medical diagnosis that would limit exercises

  • have experienced a fall that required physician evaluation (Emergency Department, urgent care or a hospitalization) within the past year

  • Requires an assistive device or person (e.g., cane or walker) for walking, standing, balancing

  • Currently use a structured exercise regimen defined as participation in a regular exercise program consisting of more than 60 minutes per week in total

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Nevada Las Vegas Las Vegas Nevada United States 89154
2 University of Wyoming Laramie Wyoming United States 82070

Sponsors and Collaborators

  • University of Wyoming
  • University of Nevada, Las Vegas

Investigators

  • Principal Investigator: Mary Jo Cooley Hidecker, PhD, University of Wyoming
  • Study Director: Merrill Landers, DPT, Ph.D., University of Nevada, Las Vegas

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
University of Wyoming
ClinicalTrials.gov Identifier:
NCT03381898
Other Study ID Numbers:
  • 1003674
First Posted:
Dec 22, 2017
Last Update Posted:
Dec 22, 2017
Last Verified:
Dec 1, 2017
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University of Wyoming
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 22, 2017